 Scpharmaceuticals Inc NASDAQ: SCPH shares were hurtling toward their late March lows Monday after a binary event panned out negatively for the biopharma. What Happened: Burlington, Massachusetts-based scPharma said the FDA issued a complete response letter for its new drug application for Furoscix, a proprietary, subcutaneously delivered furosemide solution being evaluated as an outpatient alternative for the treatment of worsening congestive heart failure. 